每经AI快讯，宝济药业-B(02659.HK)逆市涨超6%，盘中高见190港元创新高，截至发稿，涨6.09%，报 190港元，成交额2805.61万港元。 ...

宝济药业-B(02659)逆市涨超6%，盘中高见190港元创新高，截至发稿，涨6.09%，报190港元，成交额 2805.61万港元。 消息面上，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中宝济 药业-B(02659)获纳入恒生综合指数。此次变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日 (星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据LiveReport大数据预测，宝济 药业有望借此机会纳入港股通，迎来发展新契机。 据悉，宝济药业拥有中国首款报产的重组人透明质酸酶的KJ017，用于大容量皮下给药;全球首款在低预 存抗体和给药次数方面具备"同类最佳"潜力的IgG降解酶KJ103，用于抗体介导的自身免疫性疾病; 以及 一款已获得合作验证的长效促卵泡激素药物SJ02，用于辅助生殖。西牛证券指出，就即将及正在商业化 的产品而言，宝济药业己经订下明确的商业化模式及时间表。其中，目前重组人透明质酸酶并无作为单 药疗法在中国市场销售，KJ017预计于2026年首季获得NDA批准。 ...

消息面上，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中宝济 药业-B(02659)获纳入恒生综合指数。此次变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日 (星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据LiveReport大数据预测，宝济 药业有望借此机会纳入港股通，迎来发展新契机。 据悉，宝济药业拥有中国首款报产的重组人透明质酸酶的KJ017，用于大容量皮下给药;全球首款在低预 存抗体和给药次数方面具备"同类最佳"潜力的IgG降解酶KJ103，用于抗体介导的自身免疫性疾病; 以及 一款已获得合作验证的长效促卵泡激素药物SJ02，用于辅助生殖。西牛证券指出，就即将及正在商业化 的产品而言，宝济药业己经订下明确的商业化模式及时间表。其中，目前重组人透明质酸酶并无作为单 药疗法在中国市场销售，KJ017预计于2026年首季获得NDA批准。 智通财经APP获悉，宝济药业-B(02659)逆市涨超6%，盘中高见190港元创新高，截至发稿，涨6.09%， 报190港元，成交额2805.61万港元。 ...

Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Baoyi Pharmaceutical-B (02659) being included in the Hang Seng Composite Index, effective March 9, 2026 [1] Company Summary - Baoyi Pharmaceutical has developed China's first marketed recombinant hyaluronidase KJ017 for large-volume subcutaneous administration, the world's first IgG degrading enzyme KJ103 with "best-in-class" potential in low pre-storage antibodies and dosing frequency for antibody-mediated autoimmune diseases, and a long-acting follicle-stimulating hormone drug SJ02 for assisted reproduction, indicating a transition from pure R&D to commercialization [1] - The inclusion in the Hang Seng Composite Index is expected to enhance stock liquidity and valuation premium, providing mainland investors with opportunities to allocate quality biopharmaceutical assets [1]

Core Viewpoint - Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Baoyi Pharmaceutical-B (02659) being included in the Hang Seng Composite Index, effective March 9, 2026 [1] Company Summary - Baoyi Pharmaceutical has developed China's first marketed recombinant hyaluronidase KJ017 for large-volume subcutaneous administration, and the world's first IgG degrading enzyme KJ103, which has "best-in-class" potential in terms of low pre-stored antibodies and administration frequency for antibody-mediated autoimmune diseases [1] - The company also has a long-acting follicle-stimulating hormone drug SJ02, which has been validated through collaboration for assisted reproduction [1] - These three core products are in various stages of commercialization, new drug application registration, or later clinical stages in China, indicating a transition from pure research and development to commercialization for Baoyi Pharmaceutical [1] Industry Summary - The adjustment of Hong Kong Stock Connect eligible stocks is often seen as a market barometer [1] - If Baoyi Pharmaceutical successfully enters the Stock Connect, it is expected to significantly enhance stock liquidity and valuation premium, providing mainland investors with new opportunities to allocate quality biopharmaceutical assets [1]

Core Viewpoint - Baoyi Pharmaceutical-B (02659) has seen its stock price rise over 440% from its IPO price of 26.38 HKD, reaching a high of 143 HKD, indicating strong market interest and potential for future growth [1][5]. Group 1: Company Overview - Baoyi Pharmaceutical has developed three core products: KJ017, a recombinant hyaluronidase for large-volume subcutaneous administration; KJ103, an IgG degrading enzyme with "best-in-class" potential for autoimmune diseases; and SJ02, a long-acting follicle-stimulating hormone for assisted reproduction [1][5]. - These products are in various stages of commercialization, new drug application registration, or late-stage clinical trials in China, signaling a transition from pure research to commercialization for Baoyi Pharmaceutical [1][5]. Group 2: Financial Outlook - According to a report from Xiniu Securities, Baoyi Pharmaceutical has established a clear commercialization model and timeline, with expectations that its products will start contributing significantly to revenue by 2026, primarily from KJ017 and SJ02 [1][5]. - KJ103, which is aimed at desensitization in kidney transplantation, is projected to begin generating revenue in 2027, while its applications for GBS and anti-GBM diseases will contribute at a later date [1][5].

Group 1 - The stock of Baoyi Pharmaceutical-B (02659.HK) increased by over 10% on February 10, reaching a price of 142.4 HKD [1] - As of the time of reporting, the stock was up by 9.88% with a trading volume of 43.2575 million HKD [1]

Core Viewpoint - Baoyi Pharmaceutical (02659) has seen its stock price increase by over 440% from its IPO price of 26.38 HKD, reaching a high of 143 HKD, indicating strong market interest and potential growth in its product pipeline [1] Group 1: Company Overview - Baoyi Pharmaceutical has developed China's first recombinant hyaluronidase KJ017 for large-volume subcutaneous administration, and the world's first IgG degrading enzyme KJ103, which shows "best-in-class" potential for low pre-storage antibodies and dosing frequency, targeting autoimmune diseases [1] - The company also has a long-acting follicle-stimulating hormone drug SJ02, which has been validated through collaboration and is aimed at assisted reproduction [1] Group 2: Commercialization and Revenue Potential - Baoyi Pharmaceutical is transitioning from a pure research phase to commercialization, with its three core products already in various stages of commercialization, new drug application registration, or late-stage clinical trials [1] - According to a report from Xiniu Securities, Baoyi has established a clear commercialization model and timeline, with expectations that products will start contributing significantly to revenue by 2026, particularly KJ017 and SJ02 [1] - The KJ103 product, used for kidney transplant desensitization, is anticipated to start generating revenue from 2027, while other applications for KJ103 will contribute at later stages [1]

Core Viewpoint - Baijia Pharmaceutical-B (02659) has seen its stock price increase by over 440% from its IPO price of 26.38 HKD, reaching a high of 143 HKD, indicating strong market interest and potential growth in its product pipeline [1] Company Overview - Baijia Pharmaceutical has developed China's first marketed recombinant hyaluronidase KJ017 for large-volume subcutaneous administration [1] - The company also has the world's first IgG degrading enzyme KJ103, which shows "best-in-class" potential in low pre-storage antibody and administration frequency, targeting antibody-mediated autoimmune diseases [1] - Additionally, Baijia has a long-acting follicle-stimulating hormone drug SJ02, which has been validated through collaboration and is aimed at assisted reproduction [1] Commercialization Progress - The three core products have entered commercialization, new drug application registration, or late-stage clinical trials in China, indicating a transition from pure R&D to commercialization for Baijia Pharmaceutical [1] - According to a report from Xiniu Securities, Baijia has established a clear commercialization model and timeline, with expectations for significant revenue contributions starting in 2026 from KJ017 and SJ02 [1] - KJ103, which is applied in kidney transplant desensitization, is anticipated to start contributing to revenue in 2027, with further applications for GBS and anti-GBM diseases expected to follow at a later date [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 FF301 第 1 頁 共 10 頁 v 1.2.0 致：香港交易及結算所有限公司 公司名稱: 上海寶濟藥業股份有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02659 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 154,327,250 | RMB | | 0.2 | RMB | | 30,865,450 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 154,327,250 | RMB | | 0.2 | RMB | | 30 ...